BASIC AND CLINICAL STUDIES ON CEFDINIR, A NEW ORAL CEPHALOSPORIN ANTIBIOTIC, IN THE SURGICAL FIELD

• Published in: CHEMOTHERAPY Vol. 37; no. Supplement2; pp. 660 - 670
• Main Author: IWAI, SHIGETOMI
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1989
• Subjects: Cefdinir
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.37.Supplement2_660

We perfomed basic and clinical studies on cefdinir (CFDN), a new oral cephalosporin, with the following results. The antibacterial activity of CFDN against clinical isolates was compared with that of ampicillin (ABPC), methicillin (DMPPC), flucloxacillin (MFIPC), cephalexin (CEX), cefaclor (CCL), lincomycin (LCM), clindamycin (CLDM), minocycline (MINO), norfloxacin (NFLX), and ofloxacin (OFLX). The minimum inhibitory concentrations of CFDN were determined against clinical isolates of coagulase-positive and- negative staphylococci, Enterococcus faecalis, Escherichia coli and Klebsiella pneumoniae. The drug was active aganist staphylococci, but less active against E. faecalis. It had also potent antibacterial activity against E. coli and was even more potent activity against K. pneumoniae. In the clinical study, CFDN was administered to 25 patients with infections of the skin and soft tissue. Clinical response was excellent in 9 patients, good in 12, fair in 2, poor in 1, and unknown in 1, with an efficacy rate of 87.5%. No side effects were observed except slight diarrhea in 1 and pruritic eruption in 1.